查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1692168

濕疹治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、配銷通路、地區和競爭細分，2020-2030 年預測

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球濕疹治療市場價值為 132.5 億美元，預計在預測期內將實現令人矚目的成長，到 2030 年的複合年成長率為 7.46%。全球濕疹治療市場是指致力於治療濕疹的製藥和醫療保健行業，濕疹是一種以發炎、搔癢和發紅為特徵的慢性皮膚病。該市場涵蓋各種產品，包括外用藥膏、軟膏、口服藥物和生物製劑，旨在緩解濕疹症狀和控制病情。根據美國國家濕疹協會估計，3,160 萬美國人患有濕疹，而且由於污染、生活方式的改變和化學物質的接觸，濕疹病例預計還會增加。濕疹盛行率的不斷上升推動了對有效治療的需求，促進了濕疹治療市場的擴張。隨著越來越多的人尋求緩解，製藥公司正在投資創新解決方案來治療這種慢性皮膚病。

市場概況
預測期 2026-2030
2024 年市場規模 132.5 億美元
2030 年市場規模 202.4 億美元
2025-2030 年複合年成長率 7.46％
成長最快的領域 網路藥局
最大的市場 北美洲

主要市場促進因素

濕疹盛行率上升

主要市場挑戰

多元化的患者群體

主要市場趨勢

生物療法帶來治療革命

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球濕疹治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療（抗生素、抗組織胺、鈣調磷酸酶抑制劑、皮質類固醇、潤膚劑和保濕劑、免疫調節劑、白血球介素抑制劑）
    • 按配銷通路（醫院和診所、網路藥局、零售藥局）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按治療
    • 按配銷通路
    • 按地區

第 6 章：北美濕疹治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲濕疹治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 法國
    • 義大利
    • 西班牙

第 8 章：亞太地區濕疹治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 日本
    • 印度
    • 澳洲
    • 韓國

第 9 章：南美洲濕疹治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲濕疹治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 合併與收購
  • 產品發布

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

    • 賽諾菲公司
      • 業務概覽
      • 產品供應
      • 最新動態
      • 財務狀況（據報告）
      • 主要人員
      • SWOT 分析
    • Encore 皮膚科公司
    • 艾伯維公司
    • F 霍夫曼-拉羅氏公司
    • 諾華公司
    • 再生元製藥公司
    • 安斯泰來製藥公司
    • 葛蘭素史克公司
    • 阿斯特捷利康公司
    • 輝瑞公司

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 18752

Global Eczema Therapeutics Market was valued at USD 13.25 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.46% through 2030. The Global Eczema Therapeutics Market refers to the pharmaceutical and healthcare sector dedicated to treating eczema, a chronic skin condition characterized by inflammation, itching, and redness. This market encompasses various products, including topical creams, ointments, oral medications, and biologics, designed to alleviate eczema symptoms and manage the condition. According to the National Eczema Association estimates that 31.6 million Americans have eczema, with cases expected to rise due to pollution, lifestyle changes, and chemical exposure. This growing prevalence is driving demand for effective treatments, fueling the expansion of the eczema therapeutics market. As more people seek relief, pharmaceutical companies are investing in innovative solutions to address this chronic skin condition.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 13.25 Billion
Market Size 2030USD 20.24 Billion
CAGR 2025-20307.46%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Eczema

The most apparent way in which the rising prevalence of eczema boosts the growth of the eczema therapeutics market is through the expanding patient population. Eczema affects people of all ages, from infants to adults, and its incidence has been steadily climbing. This larger pool of potential patients translates into a growing demand for effective treatments, thereby driving market growth. For instance, according to the National Eczema Association reports that eczema affects over 30 million Americans, with a prevalence of 10%-20% in children and 2%-5% in adults, highlighting its widespread impact and the need for effective treatments across different age groups.

As eczema continues to affect a greater number of individuals and families, awareness of the condition has risen significantly. Patients and their caregivers are increasingly seeking medical advice and treatment options. This growing awareness contributes to early diagnosis and intervention, fostering the adoption of eczema therapeutics and driving market expansion.

Eczema is a chronic condition that can significantly impact a person's quality of life. The constant itching, discomfort, and the potential for skin infections drive individuals to seek solutions that provide relief and long-term management. This demand for effective treatments encourages pharmaceutical companies and researchers to invest in the development of innovative therapies.

Key Market Challenges

Diverse Patient Population

One of the primary challenges faced by the eczema therapeutics market is the diverse nature of the patient population. Eczema can manifest differently in individuals, with varying triggers and severity levels. Tailoring treatments to the specific needs of each patient can be complex and requires a personalized approach. Pharmaceutical companies are increasingly investing in research to address this challenge by developing more targeted therapies.

Key Market Trends

Biologic Therapies Revolutionizing Treatment

Biologic drugs have already made a significant impact on the eczema therapeutics market, but their potential is far from exhausted. In the coming years, we can expect to see the development of more targeted and efficient biologics that offer even better results with fewer side effects. These innovative therapies are likely to become more accessible to a broader range of eczema patients.

Key Market Players

  • Sanofi SA
  • Encore Dermatology Inc.
  • AbbVie Inc.
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • GSK PLC
  • AstraZeneca PLC
  • Pfizer Inc.

Report Scope:

In this report, the Global Eczema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Eczema Therapeutics Market, By Treatment:

  • Antibiotics
  • Antihistamines
  • Calcineurin Inhibitors
  • Corticosteroids
  • Emollients & Moisturizers
  • Immunomodulators
  • Interleukin Inhibitors

Eczema Therapeutics Market, By Distribution Channel:

  • Hospital & Clinics
  • Online Pharmacies
  • Retail Pharmacies

Eczema Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Eczema Therapeutics Market.

Available Customizations:

Global Eczema Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Eczema Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 5.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Eczema Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 6.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Eczema Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Eczema Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Eczema Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Distribution Channel

7. Europe Eczema Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 7.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Eczema Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. United Kingdom Eczema Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. France Eczema Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Eczema Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Eczema Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Eczema Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 8.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Eczema Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Japan Eczema Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. India Eczema Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Australia Eczema Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. South Korea Eczema Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Distribution Channel

9. South America Eczema Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 9.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Eczema Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Eczema Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Eczema Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Eczema Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 10.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Eczema Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Eczema Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Eczema Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Distribution Channel
    • 10.3.4. Kuwait Eczema Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment
        • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

    • 14.6.1. Sanofi SA
      • 14.6.1.1. Business Overview
      • 14.6.1.2. Product Offerings
      • 14.6.1.3. Recent Developments
      • 14.6.1.4. Financials (As Reported)
      • 14.6.1.5. Key Personnel
      • 14.6.1.6. SWOT Analysis
    • 14.6.2. Encore Dermatology Inc
    • 14.6.3. AbbVie Inc
    • 14.6.4. F Hoffmann-La Roche AG
    • 14.6.5. Novartis AG
    • 14.6.6. Regeneron Pharmaceuticals Inc
    • 14.6.7. Astellas Pharma Inc
    • 14.6.8. GSK PLC
    • 14.6.9. AstraZeneca PLC
    • 14.6.10. Pfizer Inc

15. Strategic Recommendations

16. About Us & Disclaimer